When we undergo IV therapy for skin, we are essentially sending a stop signal to this enzyme
Now, the aim is to complete the dose-optimisation studies for the once-daily formulation as quickly as possible with a target of the first quarter of 2025 to allow registration trials to get underway later that year
( 10.1056/NEJMoa1509225) [DOI] [PubMed] [Google Scholar] 108.Marso SP, Daniels GH, Frandsen KB, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LSet al
10.3390/biom6010006 94 imiG.Babi LekoM.WrayS.HarringtonC
When sourced from licensed, FDA-regulated compounding pharmacies and prescribed under a doctors regular care, these alternatives are safe and effective